Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)

被引：16

作者：

Maeda, Haruka ^{[1
,2
]}

Saito, Nobuo ^{[3
]}

Igarashi, Ataru ^{[4
,5
]}

Ishida, Masayuki ^{[6
]}

Suami, Kazuya ^{[7
]}

Yagiuchi, Ai ^{[7
]}

Kimura, Yuya ^{[8
]}

Komino, Masaru ^{[8
]}

Arai, Hiromi ^{[8
]}

Morikawa, Toru ^{[9
]}

Motohashi, Iori ^{[10
]}

Miyazawa, Rei ^{[10
]}

Moriyama, Tetsu ^{[11
]}

Kamura, Hiroshi ^{[12
]}

Terada, Mayumi ^{[13
]}

Kuwamitsu, Osamu ^{[14
]}

Hayakawa, Tomoichiro ^{[15
]}

Sando, Eiichiro ^{[16
,17
]}

Ohara, Yasuji ^{[18
]}

Teshigahara, Osamu ^{[19
]}

Suzuki, Motoi ^{[20
]}

Morimoto, Konosuke ^{[1
]}

机构：

[1] Nagasaki Univ, Inst Trop Med, Dept Resp Infect, 1-12-4 Sakamoto, Nagasaki 8528523, Japan

[2] Nagasaki Univ, Dept Clin Trop Med, Grad Sch Biomed Sci, Nagasaki, Japan

[3] Oita Univ, Fac Med, Dept Microbiol, Oita, Japan

[4] Yokohama City Univ, Unit Publ Hlth & Prevent Med, Sch Med, Yokohama, Kanagawa, Japan

[5] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Econ & Outcomes Res, Tokyo, Japan

[6] Chikamori Hosp, Kochi, Japan

[7] Nagoya Ekisaikai Hosp, Nagoya, Aichi, Japan

[8] Saiseikai Kurihashi Hosp, Saitama, Japan

[9] Nara City Hosp, Nara, Japan

[10] Kawasaki Municipal Tama Hosp, Kawasaki, Kanagawa, Japan

[11] Moriyama Mem Hosp, Tokyo, Japan

[12] Loco Clin Nakameguro, Tokyo, Japan

[13] Nijigaoka Hosp, Nagasaki, Japan

[14] Gohongi Clin, Tokyo, Japan

[15] Hayakawa Internal Med Clin, Fukuoka, Japan

[16] Kita Fukushima Med Ctr, Fukushima, Japan

[17] Fukushima Med Univ, Fukushima, Japan

[18] Takagi Hosp, Nagoya, Aichi, Japan

[19] Mizuho St Clin, Nagoya, Aichi, Japan

[20] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan

来源：

CLINICAL INFECTIOUS DISEASES | 2022年 / 75卷 / 11期

关键词：

SARS-CoV-2; COVID-19; vaccine effectiveness; Delta; Japan;

D O I：

10.1093/cid/ciac292

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This multicenter test-negative case-control study showed messenger RNA COVID-19 vaccine effectiveness against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Japan during July-September 2021: 88.7% among people aged 16-64 years and 90.3% among those aged >= 65 years. Background Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant. Methods We conducted a multicenter test-negative case-control study in patients aged >= 16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, when the Delta variant was dominant (>= 90% of SARS-CoV-2 infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16-64 years was also assessed. Results We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving 2 doses >= 14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8%-93.9%) among patients aged 16-64 years and 90.3% (95% CI, 73.6%-96.4%) among patients aged >= 65 years. Among patients aged 16-64 years, vaccine effectiveness was 91.8% (95% CI, 80.3%-96.6%) within 1-3 months after full vaccination, and 86.4% (95% CI, 56.9%-95.7%) within 4-6 months. Conclusions mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July-September 2021, when the Delta variant was dominant nationwide.

引用

页码：1971 / 1979

页数：9

共 50 条

[21] The liver in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
Davidov-Derevynko, Yana
Ben Yakov, Gil
Wieder, Anat
Segal, Gad
Naveh, Lior
Orlova, Natalia
Gringauz, Irina
Amit, Sharon
Mor, Orna
Klempfner, Robert
Rahav, Galia
Ben Ari, Ziv
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E313 - E319
[22] Pathology and pathogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Afewerky, Henok Kessete
EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 245 (15) : 1299 - 1307
[23] JMM Profile: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Inglis, Timothy J. J.
Mathee, Kalai
JOURNAL OF MEDICAL MICROBIOLOGY, 2021, 70 (03)
[24] Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA in the Human Eye
Kamalipour, Alireza
Ashraf, Mohammad Ali
Moghimi, Sasan
Moattari, Afagh
Ashraf, Mohammad Javad
Abbasi, Farhad
Azodi, Farzan
Oboudi, Shadi
Pirbonyeh, Neda
Mokhtaryan, Maryam
Roshanshad, Amirhossein
Do, Jiun L.
Weinreb, Robert N.
OCULAR IMMUNOLOGY AND INFLAMMATION, 2023, 31 (01) : 32 - 38
[25] Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population
Butt, Adeel A.
Talisa, Victor B.
Yan, Peng
Shaikh, Obaid S.
Omer, Saad B.
Mayr, Florian B.
CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E579 - E584
[26] Iodine mouthwashes as deterrents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Blasi, Claudio
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2021, 42 (12): : 1541 - 1542
[27] A review of metallic nanostructures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Istuti Saraswat
Sarmistha Saha
Anuja Mishra
Toxicology and Environmental Health Sciences, 2023, 15 : 315 - 324
[28] A review of metallic nanostructures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Saraswat, Istuti
Saha, Sarmistha
Mishra, Anuja
TOXICOLOGY AND ENVIRONMENTAL HEALTH SCIENCES, 2023, 15 (04) : 315 - 324
[29] Epidemiology of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Wei, Maoti
Yang, Ning
Wang, Fenghua
Zhao, Guoping
Gao, Hongwei
Li, Yuming
DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS, 2020, 14 (06) : 796 - 804
[30] SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines
Thiruvengadamt, Ramachandra
Binayket, Akshay
Awasthi, Amit
LANCET INFECTIOUS DISEASES, 2022, 22 (03): : 301 - 302

← 1 2 3 4 5 →